Allogene Therapeutics, Inc. (ALLO) has 8 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 1 sales totalling $63K. Most recent filing: Aug. 25, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 25, 2026 filed Aug. 21, 2026 | Douglas Earl Martin SVP, General Counsel | −$62,958 | 29,697 | −6% | No | |
|
|
||||||
| July 6, 2026 filed July 1, 2026 | Roberts Zachary President and CEO | $0 | 610,720 | 0% | No | |
|
|
||||||
| June 23, 2026 filed June 18, 2026 | Kazam Joshua A Director | $0 | 190,800 | +100% | No | |
|
|
||||||
| June 23, 2026 filed June 18, 2026 | MESSEMER DEBORAH M. Director | $0 | 95,400 | 0% | No | |
|
|
||||||
| June 23, 2026 filed June 18, 2026 | Mayo Stephen Director | $0 | 144,400 | 0% | No | |
|
|
||||||
Showing the 5 most recent of 8 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free